Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 24.01.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appo |
| 03.04.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ction 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appoin |
Stammdaten
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Unternehmen & Branche
| Name | Summit Therapeutics Inc. |
|---|---|
| Ticker | SMMT |
| CIK | 0001599298 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 16,58 Mrd. USD |
| Beta | -1,37 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -1,079,586,000 | -1.44 | 751,182,000 | 658,860,000 | |
| 2025-09-30 | 10-Q | -231,793,000 | -0.31 | 261,729,000 | 192,263,000 | |
| 2025-06-30 | 10-Q | -565,708,000 | -0.76 | 324,037,000 | 259,439,000 | |
| 2025-03-31 | 10-Q | -62,913,000 | -0.09 | 383,822,000 | 344,330,000 | |
| 2024-12-31 | 10-K | 0 | -221,315,000 | -0.31 | 435,560,000 | 388,748,000 |
| 2024-09-30 | 10-Q | 0 | -56,254,000 | -0.08 | 502,852,000 | 437,920,000 |
| 2024-06-30 | 10-Q | -60,385,000 | -0.09 | 341,856,000 | 195,075,000 | |
| 2024-03-31 | 10-Q | -43,473,000 | -0.06 | 176,781,000 | 44,210,000 | |
| 2023-12-31 | 10-K | 0 | -614,928,000 | -0.99 | 202,949,000 | 77,692,000 |
| 2023-09-30 | 10-Q | 0 | -21,268,000 | -0.03 | 218,476,000 | 99,379,000 |
| 2023-06-30 | 10-Q | 0 | -14,717,000 | -0.02 | 237,372,000 | 119,599,000 |
| 2023-03-31 | 10-Q | 0 | -542,376,000 | -1.43 | 254,897,000 | 133,482,000 |
| 2022-12-31 | 10-K | 705,000 | -78,782,000 | -0.41 | 664,168,000 | 126,654,000 |
| 2022-09-30 | 10-Q | 220,000 | -21,385,000 | -0.10 | 155,327,000 | 133,248,000 |
| 2022-06-30 | 10-Q | 235,000 | -16,771,000 | -0.12 | 95,718,000 | 51,317,000 |
| 2022-03-31 | 10-Q | 250,000 | -21,397,000 | -0.15 | 116,472,000 | 64,407,000 |
| 2021-12-31 | 10-K | 1,809,000 | -88,602,000 | -0.67 | 113,374,000 | 83,284,000 |
| 2021-09-30 | 10-Q | 1,309,000 | -19,599,000 | -0.20 | 128,673,000 | 102,298,000 |
| 2021-06-30 | 10-Q | 57,000 | -24,416,000 | -0.27 | 145,517,000 | 119,427,000 |
| 2021-03-31 | 10-Q | 192,000 | -17,488,000 | -0.21 | 140,794,000 | 64,405,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-10-21 | DUGGAN ROBERT W | Director, Officer, 10% Owner, Co-Chief Executive Officer | Open Market Purchase | 26,680 | 18.74 | 499,983.20 | +15,2% | |
| 2025-10-21 | Xia Yu | Director | Open Market Purchase | 533,617 | 18.74 | 9,999,982.58 | +304,8% | |
| 2025-10-21 | Zanganeh Mahkam | Director, Officer, 10% Owner, Co-Chief Executive Officer | Open Market Purchase | 26,680 | 18.74 | 499,983.20 | +15,2% | |
| 2025-09-11 | DUGGAN ROBERT W | Director, Officer, 10% Owner, Co-Chief Executive Officer | Open Market Purchase | 5,000 | 18.07 | 90,350.00 | +2,8% | |
| 2025-09-11 | Zanganeh Mahkam | Director, Officer, 10% Owner, Co-Chief Executive Officer | Open Market Purchase | 5,000 | 18.07 | 90,350.00 | +2,8% | |
| 2025-09-10 | Zanganeh Mahkam | Director, Officer, 10% Owner, Co-Chief Executive Officer | Open Market Purchase | 333,394 | 17.68 | 5,894,405.92 | +179,6% | |
| 2025-09-10 | DUGGAN ROBERT W | Director, Officer, 10% Owner, Co-Chief Executive Officer | Open Market Purchase | 333,394 | 17.68 | 5,894,405.92 | +179,6% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.